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Abstract
Fibromyalgia (FM) has been described as a chronic cli-
nical condition related to multisensory hypersensitivity 
presenting with a complex of symptoms dominated by 
chronic widespread pain associated with the existence of a 
range of co-morbidities, such as fatigue, sleep disturbance, 
cognitive impairment, anxiety and depression. Current 
treatments include drugs that target serotonin and nor-
adrenaline levels within the central nervous system, e.g. , 
tricyclic antidepressants, serotonin noradrenaline reuptake 
inhibitors, and voltage-gated calcium channel subunit 
ligands, e.g. , gabapentin and pregabalin. Investigation 
of a range of novel targets, such as melatoninergic, 
cannabinoid, dopamine, NMDA, angiotensin, orexin and 
opioid receptors, and ion channels, in addition revisiting 
bioamine modulation and subunits has provided efficacy 
outcomes that improve the health status of patients 
with FM. Nevertheless, modest and limited efficacy is 
often observed reflecting the heterogeneity of FM with 
existence of subpopulations of patients, the contribution of 
peripheral and central components to the pathophysiology, 
and the extensive range of accompanying co-morbidities. 
The complexity and multidimensional nature of FM is 
emphasized by the diversity of pharmacological targets 
gaining interest. Clues to underlying mechanisms which 
offer themselves as novel and potential targets for new 
medications are being provided by advances in the 
understanding of the pathophysiology of FM.
Key words: Fibromyalgia; Chronic pain; Fatigue; Central 
sensitization; NMDA receptors; Melatonin receptors; Gaba-
pentanoids
© The Author(s) 2017. Published by Baishideng Publishing 
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Core tip: Fibromyalgia (FM) is a multidimensional chronic 
pain condition that current therapies provide modest and 
limited eficacy due to the heterogeneity of the condition, 
contribution of peripheral and central components to the 
pathophysiology, and a range of co-morbidities. Drugs 
acting on novel and existing targets, such as melatoninergic, 
cannabinoid, dopamine, NMDA, angiotensin, orexin and 
opioid receptors, ion channels, bioamine processes and 
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subunits have provided eficacy outcomes that improve the 
health status of patients with FM. An understanding of the 
pathophysiology of FM is providing potential targets for new 
medications.
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from: URL: http://www.wjgnet.com/2220-3192/full/v6/i1/1.htm 
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INTRODUCTION
Fibromyalgia (FM) has been described as a chronic clinical 
condition related to multisensory hypersensitivity
[1,2]
. 
Thus, FM presents with a complex of symptoms do­
minated by chronic widespread pain, characterized 
by hyperalgesia and allodynia, as a consequence of 
amplified responses of the central nervous system 
(CNS) to peripheral sensory input leading to enhanced 
neuronal excitability. It is further complicated by the 
existence of a range of co­morbidities, such as fatigue, 
sleep disturbance, cognitive impairment, anxiety and 
depression, which present with variable intensity
[1,2]
.  
EpidemiologyThe classi cation of FM has often been based on fulilment 
by the patient of the American College of Rheumatology 
(ACR) 1990 criteria which require a history (at least 3 
mo) of widespread pain in all 4 quadrants of the body 
and pain in 11 of 18 tender point sites at 9 symmetrical 
locations
[3]
. Application of the ACR 1990 criteria has 
resulted in the reporting of the prevalence of FM to be 
0.4%­8% of the population with the condition being more 
common in females than males
[4,5]
. As a consequence, FM presents a major inancial and social burden to patients 
and healthcare systems. Although the ACR 1990 criteria 
are often used for diagnosis they were developed for research classi cation of FM and are focused to the pain 
and subjective tender point score with no consideration of 
the other symptoms characteristic of FM. The subjectivity 
of the current diagnostic approach and the lack of bio­
chemical tests for FM have led to many patients that would fulil the ACR 1990 FM criteria remaining undiagnosed[6,7]. 
Thus, to accommodate the spectrum of symptoms and 
remove reliance on tender points 2010 ACR criteria were 
developed to assess somatic symptom (sleep disturbance, 
cognitive disturbance and fatigue) severity and 
widespread pain
[8]
. A 2016 update was published based 
on the assessment of validation studies comparing the 2010 criteria with the ACR 1990 classi cation and clinical 
criteria
[9]
. The 2016 revision puts emphasis on generalised 
pain criterion to limit misclassification of regional pain 
disorders, recommends use of the FM symptom scale (FS 
scale), eliminates recommendation regarding diagnostic 
exclusion by the return to original 1990 proposal that “FM 
remains a valid construct irrespective of other diagnoses”, 
and combines “physician” and “patient self­report” criteria 
into a single set. 
PATHOPHYSIOLOGY
Neuronal excitability associated with amplified res­
ponses to peripheral input of the CNS leading to central 
sensitization (CS) is believed to be an underlying patho­
physiology of FM
[1,2]
. The enhanced excitability of the neurophysiology relects altered neurotransmitter function 
and possible neuroplasticity leading to augmented sensory 
processing
[10]
. Peripheral nociceptive generators, such as 
nerve pathologies, neuro­inflammation, skeletal muscle 
abnormalities and ischaemia, have been reported to play 
a role in the enhanced activity of the central components 
and thereby the symptoms
[11,12]
. Thus, the chronic pain 
experience of patients with FM is consistent with balance 
shifts to an enhanced excitation and reduced inhibition 
within the CNS. 
Altered biochemistry in FM, where increased con­
centrations of substance P (2 to 3­fold), endogenous 
opioids (3 to 4­fold), glutamine (2­fold), nerve growth 
factor (4­fold) and brain­derived neurotrophic factor (2 
to 4­fold) in the cerebrospinal fluid (CFS) have been 
observed, is consistent with the wind­up phenomenon 
(a progressive increase in response reflective of slow 
temporal summation) leading to self­sustaining CS
[1,13]
. 
In healthy subjects, application of intense painful 
stimuli activates the diffuse noxious inhibitory control 
(DNIC), leading to a whole­body analgesia, which involves 
descending opioidergic and serotonergic­noradrenergic 
efferent pathways from the brain to the spinal cord that 
downregulate the pain signal. DNIC has consistently been 
reported to be reduced or absent in FM, compared to 
healthy controls
[14]
. An altered biochemistry of serotonin 
and noradrenaline in the cerebrospinal fluid (CSF) and 
serum is consistent with a decreased endogenous sero­
tonergic and noradrenergic activity associated with 
reduced DNIC in FM patients. The CFS levels of 5­hydroxy 
indoleacetic acid (5­HIAA), the main metabolite of sero­
tonin, and 3­methoxy­4­hydroxyphenylglycol (MHPG), 
the main metabolite of noradrenaline, and blood levels of 
L­tryptophan and serotonin are lower in patients with FM 
compared to healthy controls
[1,13]
. In contrast, data from 
FM patients indicates high baseline occupancy of opioid receptors rather than a deiciency of endogenous opioid 
release, as a consequence of normal or increased (3 to 
4­fold) endogenous opioid activity
[13]
.
Alterations in the hypothalamic pituitary adrenal 
axis (HPA), and autonomic and cardiovascular system 
associated with systemic stress­related effects have also 
been proposed to enhance or underlie the symptoms, 
particularly the pain, of FM
[2,13]
. However, studies in patients 
with FM regarding alterations of these stress systems, 
are often inconsistent with abnormal HPA or autonomic 
function in only a small proportion of patients with marked 
patient and healthy subject overlap. In contrast, HPA and 
autonomic abnormalities have been suggested to be a 
consequence of the pain in FM patients
[15]
.
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Although the pathophysiology of FM has been suggested to involve an inlammatory component, studies of cytokines have provided variable indings and have several limitations 
which could influence the outcomes
[1,2,13]
. Thus, the role 
of cytokines in FM have been questioned because of the 
inconsistency of measurements and lack of correlation 
with parameters of the disease
[16]
. The generation and 
enhancement of chronic pain characteristic of FM may be associated with raised pro-inlammatory cytokines, however 
it is not possible to conclude whether the inflammatory 
response is the cause of the symptoms or due to the 
changed physiology initiating the pain. Clinical trials have 
indicated no or very limited efficacy of anti­inflammatory 
drugs, such as non­steroidal anti­inflammatory drugs 
(NSAIDS) and steroids, in the treatment of FM consistent with a lack of a role of inlammation[2,13].    
TREATMENT STRATEGIES
Pharmacological and non­pharmacological therapeutic 
approaches are often required as treatments of the 
challenges associated with FM with drug therapy often 
focused towards the individual symptoms primarily 
the pain
[1,2,9]
. The complexity of FM has identified that 
psychological and social factors along with biological 
variables are associated with a biopsychosocial model
[17]
. 
Thus biological, psychological, and social factors require 
to be simultaneously addressed. As a consequence, 
non­pharmacological treatments such as acupuncture, 
biofeedback, cognitive behavioural therapies, exercise, 
hydrotherapy, hyperbaric oxygen therapy, mindfulness/
mind­body therapy, massage, transcranial magnetic 
stimulation, have been evaluated for the management of 
the symptoms of FM.
Acupuncture has been shown to reduce pain in various 
pain conditions, including FM
[18]
. It has been proposed 
that acupuncture reduces inflammation, causes the 
release of endorphins and creates a calmer mind. The 
analgesic effects of acupuncture may be associated with 
the adenosine metabolised from released adenosine 
triphosphate (ATP) activating adenosine A1 receptors
[19]
. 
In patients with FM, acupuncture demonstrated a 
small improvement in pain and fatigue
[18]
. Psychological 
and mind­body therapies, which include biofeedback, 
mindfulness, relaxation, incorporate strategies to improve 
psychological and physical well­being. In patients with FM 
mind­body therapies have been suggested to improve 
physical functioning, pain and mood, however due to 
the inconsistency in the design of studies the quality of 
the evidence is low
[20]
. Cognitive behavioural therapies 
provided sustained (up to 6 mo) reduction of pain, 
negative mood and disability in patients with FM
[21]
.
Many patients with FM are deconditioned and thereby 
will gain from activity programs that involve the activation 
of endogenous analgesic conditions and increase well­
being
[22]
. In trials of aerobic exercise and resistance 
training improvement in pain, physical function and well­
being has been observed
[23]
. Although land and aquatic 
exercise were reported to be equally effective, for severely 
deconditioned individuals hydrotherapy or exercising in 
water may be particularly valuable
[23,24]
. 
Increasing oxygen concentration by hyperbaric oxygen 
therapy (HBOT) can induce neuroplasticity leading to 
repair of chronically impaired brain functions which may 
change the brain metabolism and glial function to rectify 
FM­associated brain abnormal activity
[25,26]
. In a study 
of patients with FM HBOT led to improvement of all FM 
symptoms, with significant changes in pain, physical 
function and quality of life assessments
[27]
. Although these 
outcomes are encouraging HBOT requires further study as 
a treatment for FM.
There is evidence of transcranial magnetic stimulation 
(rTMS) being effective in reducing the severity of the 
pain in patients with FM which has led to the use of 
this treatment approach for at least a decade
[28]
. Other 
studies of rTMS as a treatment of FM however remain 
inconclusive questioning the routine recommendation of 
this method
[29­31]
.
The pharmacological treatments of FM are primarily 
aimed at lowering levels of pronociceptive excitatory 
neurotransmission or/and increasing antinociceptive 
neurotransmission in the CNS. Current treatments (Table 
1) include drugs that target serotonin and noradrenaline 
levels, e.g., tricyclic antidepressants, serotonin nora­
drenaline reuptake inhibitors (SNRIs), or voltage­
gated calcium channel subunit ligands, e.g., gabapentin 
and pregabalin
[2,9]
. The modulation of serotonin and 
noradrenaline levels has led to a reduction of pain, de­
pression and fatigue, and an improvement of quality of 
life in patients with FM supporting the involvement of the 
low levels of these neurotransmitters in the pathogenesis 
of FM
[2,9]
. Voltage­gated calcium channel subunit ligands 
decrease calcium influx with a reduction of the release 
of neurotransmitters that transmit, at least nociceptive 
signals reducing pain, anxiety and fatigue and improving 
sleep in patients with FM. Although the bioamine mod­
ulators and the ligands demonstrate efficacy in the 
management of FM symptoms, the outcomes are limited 
with only a proportion of patients experiencing a partial 
reduction of symptom severity. The limitation of the 
effectiveness of current medications is exacerbated by 
the incidence of adverse effects leading many patients to 
discontinue use
[32,33]
.  
Suppression of neuronal excitability and neuro­
transmitter release appears to be a key pharmacological 
property to the management of FM as observed with 
the ligands and the bioamine modulators. Clues to under­
lying mechanisms as potential targets for new and novel 
medications are becoming available through advances 
in the understanding of the pathogenesis of FM. The 
complexity of FM is emphasized by the diversity of phar­
macological targets gaining interest (Table 2). The alteration 
at both central and peripheral levels of multiple biological 
mechanisms and systems has however presented a 
complex pathophysiology with a lack of clarity which pro­
cesses are a cause or consequence of FM.  Inconsistent 
success of current treatments has led to the investigation 
of a range of novel targets, such as melatoninergic, 
Lawson K. Emerging pharmacological ibromyalgia treatment strategies
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cannabinoid, dopamine, NMDA, angiotensin, orexin and 
opioid receptors, and ion channels, in addition revisiting 
bioamine modulation and a2d ligands (Tables 2 and 3). This 
article will focus on emerging pharmacological strategies 
involving many of these targets.
EMERGING THERAPIES
Bioamine modulation
The clinical symptoms of FM have been associated with 
altered bioaminergic neurotransmitters (noradrenaline, 
serotonin and dopamine) and involvement of serotonin and 
noradrenaline in several aspects of the pathophysiology 
of FM has, for example, been supported by the tricyclic 
antidepressant amitriptyline correlated the clinical response 
with normalization of neuronal function of areas such as the 
bilateral thalamus and basal ganglia
[59]
. Further, dopamine deiciency in the regulation of pain processes and chronic 
stress has been implicated in the pathophysiology of FM
[60]
. 
Drugs (droxidopa, esreboxetine, mirtazapine, pramipexole, 
TD­9855, cyclobenzaprine, trazodone) that modulate 
the bioamine system by targeting receptors, reuptake 
processes and neurotransmitter availability either individual or in various combination have demonstrated eficacy in the treatment of FM with a reduction in pain and ibromyalgia 
impact questionnaire scores (FIQ) (Table 2). Although 
dopamine release into the basal ganglia in response to 
painful stimuli is attenuated or absent, outcomes with 
dopamine receptor agonists have been inconsistent with 
pramipexole, but not ropinirole and terguride, improving 
symptoms in studies with FM patients
[48,61,62]
. The design of 
the clinical trials being single dose monotherapy has limited 
comparison of the outcomes of the different treatments and 
thereby mechanisms. Whilst enhancement of the activity of 
the serotonergic, noradrenergic and dopaminergic pathways demonstrate beneit in the management of FM symptoms, further studies are required to identify the preferable proile of drug activity and patient proile that will proit. 
Gabapentanoids
The gabapentanoid ligands, gabapentin and pregabalin, 
are used regularly in FM patients to improve quality of 
life through the reduction of pain, sleep dysfunction and 
fatigue
[63]
. The gabapentanoids have been suggested to 
down regulate brain glutamate release and inhibit astrocyte 
induction of glutamatergic synapse formation
[64]
. Thus, 
the analgesia observed with pregabalin and gabapentin 
in clinical settings has been suggested to be linked to the 
modulation of glutamatergic activity and functional brain 
connectivity. Interestingly, FM patients with the highest 
levels of glutamate were the most likely to respond to 
pregabalin decreasing glutamatergic activity in the insula
[65]
. 
Further, short­term pregabalin treatment of FM patients 
reduced brain gray matter volume assessed by voxel­
based morphometry within the posterior insula bilaterally 
and in the medial frontal gyrus
[64]
. The gray matter volume 
reductions were associated with reductions in evoked pain­
pressure assessed functional brain connectivity and reduced 
clinical pain. 
The analgesic effects and CNS side effects of the 
gabapentanoids have been associated with subtypes of 
the subunits
[66]
. The a2d­1 subunit has been shown to 
be primarily responsible for the analgesic effects and the 
CNS side effects involve binding of the drugs to the a2d­2 
subunit
[66]
. Preferentially selective a2d­1 subunit ligands 
could provide a more successful therapeutic option with a clinically preferable eficacy/safety proile. Mirogabalin, 
a novel selective­1 subunit ligand (5­30 mg/d) reduced pain with an acceptable safety proile in diabetic peripheral 
neuropathic pain during a double­blind, randomized, 
placebo controlled study
[67]
. The potential of mirogabalin 
as a treatment of FM is being investigated in a double­
blind, randomized, placebo controlled trial and results are 
awaited
[54]
.
Opiates
An increased endogenous opioid activity observed in the 
CNS of FM patients may be related to a form of opioid 
hyperalgesia
[13]
. The use of the opioid receptor anta­
gonist naltrexone to block endogenous opioid release 
has been proposed as an effective treatment strategy in 
FM patients
[47]
. In a double­blind, randomized, placebo­
controlled study in FM patients low­dose naltrexone 
(LDN, 4.5 mg/d) reduced pain and improved mood, but 
failed to alter fatigue and sleep disorder
[47]. The beneicial 
effects observed with LDN in patients with FM have been 
suggested to involve microglia antagonism in addition to 
blocking endogenous opioid release. Pro­inflammatory 
factors released into the CNS from microglia, which may 
be abnormally sensitized in FM, could lead to central 
facilitation of the pain processing
[68]
. These outcomes 
are encouraging of LDN as a promising treatment of 
FM, however further studies are required to identify the 
value of these mechanisms of action particularly glial cell 
Table 1  Currently recommended drugs for the management of ibromyalgia[9,30,31]
Drug Mechanism of action Symptom improved
Amitriptyline Tricyclic antidepressant Pain, sleep, fatigue
Cyclobenzaprine Tricyclic antidepressant Sleep
Duloxetine Serotonin-noradrenaline reuptake inhibitor Pain, sleep
Milnacipran Serotonin-noradrenaline reuptake inhibitor Pain, fatigue
Pregabalin a2d ligand Pain, sleep, fatigue
Tramadol Weak opioid and serotonin-noradrenaline reuptake inhibitor Pain
Lawson K. Emerging pharmacological ibromyalgia treatment strategies
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Table 2  Emerging drug therapies with potential eficacy for the treatment of ibromyalgia
Drug Mechanism of action Regime Effect on pain      Secondary domains accessed Trial sponsor Ref.
VAS-P Signiicantly 
improved
No observed effect
Agomelatine Melatoninergic receptor 
agonist and 5-HT2 
receptor antagonist
25 mg/d during 
2 wk
-.06 (5.3 - 
4.07)
FIQ, anxiety, 
depression,
Sleep disorder, 
cognitive/executive 
function, quality of 
life index
University of 
Messina
[34]
25-50 mg/d 
during 2 wk
[35]
Capsaicin Transient receptor 
potential vanilloid  
subunits
Topical 0.075% 
TID during 6 wk
No signiicant 
effect
FIQ (-9.8), 
fatigue severity, 
depression, 
myalgic score, 
pressure pain 
threshold
Anxiety, physical 
functioning
Rheumatology 
Service at the 
Specialist Clinic of 
Cantabria
[36]
Dronabinol (delta-9-
tetrahydrocannabinol)
Cannabinol Daily dose 2.5 -5 
mg during 7 mo
-3.5 (7.9-4.4) Anxiety, 
depression, 
quality of life
Heidelberg 
University
[37]
Droxidopa Noradrenaline prodrug 600 mg TID 
during 9 wk
-.64 (cf pl 
-0.74)
FIQ (-9.72) Chelsea 
Therapeutics/
Lundbeck
[38]
Esreboxetine Noradrenaline reuptake 
inhibitor
4/8/0 mg/d 
during 4 wk
-.55 - .85
(cf pl -0.42 - 
-0.76)
FIQ (-3.88 to 
-7.2), PGIC 
score, GFI score 
(-0.30 to -0.64)
SF-36 physical 
function score
Pizer [39]
IMC-
Celecoxib + 
famciclovir
Viral suppression of 
herpes virus
Fixed dose 
combination 
during 6 wk
-.9 FIQ (-7.5), 
PGIC, fatigue
Innovative Med 
Concepts
[40]
Melatonin Endogenous melatonin 
receptor ligand
0 mg/d during 
6 wk
-.74 
(6.49-4.75)
FIQ (-7.7), 
sleep, tender 
points
Brazilian 
Committee for 
Development of 
Higher Education 
Personnel and 
National Council 
for Scientiic and 
Technological 
Development 
[4]
0 mg/d plus 
25 mg/d 
amitriptyline 
during 6 wk
-2. (6.96-4.86) FIQ (-24.7), 
sleep, tender 
points
Memantine NMDA antagonist 20 mg/d during 
5 mo
-.9 (cf pl -3.)
(6.9-5.0)
FIQ (-3.2), CGI, 
Quality of life 
score,
Cognitive state, 
depression
Aragon Institute of 
Health Sciences
[42]
Mirtazapine (Org 3770) a2 adrenergic and 
5-HT2 and 5-HT3 
receptor antagonist
5 mg/d during 
 wk then 30 
mg/d during 2 
wk
-.6 (cf pl -0.4) FIQ (-2.9), 
anxiety, 
depression, PGIC, 
quality of life
Meiji Seika Pharma 
Co., Ltd.
[43,44]
Nabilone Cannabinoid receptor 
agonist
0.5-.0 mg during 
4 wk
-2.04 (cf pl 
-.43)
FIQ (-2.07), 
anxiety
University of 
Manitoba
[45]
0.5-.0 mg during 
2 wk
No effect Sleep Pain, mood, quality 
of life
Winnipeg Regional 
Health Authority
[46]
Naltrexone Opioid receptor 
antagonist
4.5 mg/d during 
2 wk
-.55 (cf pl 
-0.43)
Mood Sleep, fatigue Stanford 
University
[47]
Pramipexole Dopamine agonist 4.5 mg/d during 
4 wk
-2.48 (cf pl 
-.77)
FIQ (-9.57), 
physical 
function, fatigue
Mood, depression, 
anxiety, tender 
point score
[48]
TD-9855 Noradrenaline 
serotonin reuptake 
inhibitor
20 mg/d during 
6 wk
-.4 (cf pl -0.5) FIQ (-6.2), 
PGIC, global and 
cognitive fatigue
Theravance 
Biopharm
[49]
TNX02SL 
cyclobenzaprine
Noradrenaline, 
serotonin reuptake 
inhibition, adrenergic 
and serotonin receptor 
antagonist
-4 mg/d during 
8 wk
-0.6 (cf pl -0.6) Fatigue, 
tenderness, 
sleep, 
depression
Tonix 
Pharmaceuticals
[50,5]
Trazodone 5-HT receptor 
antagonist and 
serotonin reuptake 
inhibitor
50-300 mg/d 
during 2 wk 
then trazodone/
pregabalin 
(max 450 mg/d) 
during 2 wk
-0.45 FIQ (-0), 
fatigue, 
stiffness, 
anxiety, 
depression, PGI
Universidad de 
Granada
[52]
-.29 FIQ (-3.4)
CGI: Clinical Global Impressions; FIQ: Fibromyalgia impact questionnaire; GFI: Global fatigue index; PGI: Patient global improvement; PGIC: Patient’s global 
impression of change; SF-36: 36-item short form health survey; cf pl: Compared with placebo; TID: 3 times daily; VAS-P: Visual Analog Scale of Pain based on a 0-0 
scale.
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modulation.
NMDA receptors
The glutamate NMDA receptors, particularly those within 
the dorsal horn of the spinal cord, are fundamental in 
nociceptive transmission and synaptic plasticity and thereby 
are considered a target for the treatment of neuropathic 
pain
[69]
. Elevated levels of glutamate in key pain­processing 
areas of the brain, which change in response to treatment 
that attenuates the pain, have been observed in FM 
patients
[70,71]
. NMDA receptor antagonists, ketamine, 
dextromethorphan and memantine, have shown efficacy 
in FM patients which is consistent with an attenuation of 
an increased glutaminergic activity
[2,13]
. Memantine in a 
double­blind, randomized placebo­controlled trial evoked 
a significant reduction in pain and improved quality of 
life assessment, but did not provide benefit against the 
cognitive state and depression in FM patients
[42]
. Further, an 
increase in cerebral metabolism with a correlation between 
the FIQ score and the choline levels in the posterior insula 
was reported in FM patients receiving memantine
[42]
. Use 
of memantine, like other NMDA antagonists, in the clinic is limited due to the adverse effects proile and the treatments not being well tolerated, in addition to the beneits in FM 
appear to be within a subset of patients. Several adverse 
effects of NMDA receptor antagonists are believed to be 
interference with physiological NMDA receptor function in 
the CNS
[69]
. Thus, development of NMDA receptor subtype 
specific antagonists (e.g., NR2A, NR2C, NR2D) that 
maintained the physiological function whilst suppressing 
the increased activity of glutamatergic pathways could 
offer a preferable treatment approach to FM. To target 
mechanisms that regulate NMDA receptor activity, such as 
phosphorylation sites and interacting kinases (e.g., casein 
kinase 2, Src­NADH dehydrogenase), rather than the 
channels may offer an alternative approach to improve the 
therapeutic window
[69]
. Expression levels of regulating signal 
mechanisms of NMDA receptor function were increased in 
the spinal cord neurons in a mouse model of FM, where 
hyperalgesia was induced by intramuscular acid saline 
injection
[72]
. Improved pain effects in this animal model 
implicated a reduced NMDA­pCAMKIIa­pCREB signalling 
which may represent a novel therapeutic target for FM
[72]
.
The contribution of NMDA receptor activity in the symptoms of FM has also been related to the eficacy of 
the gabapentanoid drugs. Pregabalin treatment decreased 
glutamatergic activity in the insula of FM patients
[65]
, 
further supporting the contribution of glutamatergic acti­
vity to the pathophysiology of the symptoms of FM and 
highlighting modulation as a therapeutic approach of 
interest. 
Melatonin receptors
Melatonin (N­acetyl­5­methoxytryptamine) and novel 
melatonin analogues have exhibited analgesic properties 
in addition to regulating sleep consistent with potential use 
as a therapeutic approach of chronic pain conditions such 
as FM
[73]
. Severity of pain, tender point score, sleep quality, 
depression and anxiety were significantly improved by 
melatonin (3 or 5 mg at bedtime) in studies in patients with 
FM
[41,74]
. Studies involving combined therapy of melatonin 
and the tricyclic antidepressant amitriptyline demonstrated 
superior improvement in symptoms relative to amitriptyline 
alone, but not over melatonin treatment alone
[41]
. Thus, the 
serotonergic­noradrenergic components of the descending 
endogenous pain­modulating system appeared to be 
improved by the concomitant stimulation of melatoninergic 
receptors and thereby abnormality of the melatoninergic 
system may also play a role in the pathogenesis of FM. 
Consistent with this proposal agomelatine, a melatonin 
analogue with melatoninergic receptor antagonist and 
serotonin 5­HT2C receptor antagonistic properties, im­
proved pain, depression and anxiety symptoms, but failed 
to improve sleep quality in patients with FM
[34,35]
.
Cannabinoids
The proposal of cannabinoids as a treatment of FM is 
consistent with the implication that endocannabinoids, which 
are involved in regulation of pain processing and chronic stress, are deicient in the CNS of patients with FM[75]. The 
cannabinoids nabilone (0.5­1.0 mg/d) and dronabinol (a 
synthetic form of delta­9­tetrahydrocannabinol, THC; 7.5 
mg/d) significantly reduced pain, depression and anxiety 
levels in patients with FM leading to an improvement of 
quality of life
[37,45,46]
. The incidence of adverse effects and 
drop­out rates up to 25% during the clinical trials would 
suggest the clinical use of nabilone and dronabinol may 
be limited
[37,45,46]
. The hepatic metabolites from first­pass 
metabolism of cannabinoids are believed to be responsible 
for the psychotropic effects. The transdermal delivery of 
D­(­)­glyceric acid ester of THC, ZYN001, avoids first­
pass hepatic metabolism and leads to rapid hydrolyzation 
by esterases in the skin to THC
[58,76]
. Evaluation of the 
transdermal application of ZYN001 in FM patients should provide an improved tolerability proile for a cannabinoid[58]. 
Substance P
In patients with FM the cerebrospinal fluid levels of 
substance P are raised which would lead to the activation 
of neurokinin (NK) receptors with the possibility of inducing 
pain
[13]
. NK receptor antagonists in clinical trials in FM 
and other chronic pain states either failed to demonstrate 
efficacy or provided inconsistent outcomes
[2]
. Nociceptive 
processes, however, are desensitized, due to the depletion 
of substance P, by the action of capsaicin on transient 
receptor potential vanilloid 1 subunits (TRPV1) located in 
peripheral nociceptors
[77]
. In patients with FM refractory 
to other treatments, significant improvement in myalgic 
scores, pain threshold, mood and fatigue were reported 
following topically applied capsaisin (0.075% 3 times daily 
during 6 wk)
[36]
. Although the visual analogue scale (VAS) of pain was not signi cantly changed in this study, the impact 
of FM on the patients as determined by the fibromyalgia 
impact questionnaire was reduced leading to short­term improvement. These indings are consistent with substance 
P­induced modulation of peripheral nociceptors leading to 
activation of central neuronal mechanisms responsible for 
the symptoms of FM.
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IMC-1
IMC­1 is a a proprietary fixed­dose combination of 
celecoxib, a COX­2 inhibitor, and famciclovir, an anti­viral 
nucleoside analog, that has demonstrated efficacy in 
the treatment of FM in a 16­wk, double­blind, placebo­
controlled trial
[40]
. In patients with FM, IMC­1 reduced the 
pain and fatigue, and improved the overall wellbeing as 
assessed by the fibromyalgia impact questionnaire and 
patient global impression of change. In January 2016, 
IMC­1 as a potential treatment for FM was granted “Fast 
Track” designation by the FDA
[78]
. 
Novel drugs
A number of drugs that have demonstrated efficacy 
in neuropathic pain conditions have gained interest as 
potential treatments of FM and thereby been proposed 
as candidates for clinical trials (Table 3).
EMA401 is a small molecule angiotensin II type 2 
receptor antagonist that has exhibited analgesic properties 
in postherpatic neuralgia
[79]
. FM has been identified 
as a pain condition that may gain benefit from such a 
treatment approach
[53]
. Flupirtine is an analgesic that 
exhibits KV7 channel activator properties resulting in the 
stabilization of neuronal activity
[54,80]
. A preliminary open­label study demonstrated that lupirtine had the potential 
to improve the pain, fatigue and sleep disturbance 
associated with FM
[81]
. Controlled clinical trials in FM with 
flupirtine have been proposed
[54]
. Orexin peptides and 
the two orexin receptors (A and B) play a fundamental 
role in the arousal and sleep/wake cycle
[82]
. Abnormality 
in the orexin system can lead to sleep disorders such as 
catalepsy and narcolepsy. Thus, antagonists of orexin 
receptors blocking the binding of wakefulness­promoting 
neuropeptides orexin A and orexin B to their respective 
receptor sites represent a new class of medications for 
the treatment of insomnia and other sleep disturbance 
disorders. Suvorexant is a dual orexin receptor antagonist approved by the FDA which has demonstrated eficacy in 
decreasing time to sleep onset and increasing total sleep 
time
[82]
. The investigation of suvorexant in insomnia co­
morbid with FM has been proposed with the assessment 
of effects on sleep, pain and fatigue
[56]
. Yokukansan, a 
Japanese herbal medicine, acts on the glutamatergic and 
serotonergic nervous systems and is used in the treatment 
of psychiatric disorders
[83]
. Efficacy as an analgesic has 
been demonstrated by yokukansan in neuropathic pain 
conditions with suggested greater effectiveness than 
tricyclic antidepressants, carbamazepine, gabapentin, and 
opioids
[84]
. Thus, the potential of alleviating pain in FM by 
yokukansan has been suggested, and the outcomes of 
clinical trials are awaited
[58]
. 
CONCLUSION
FM is a complex chronic pain condition where current and 
emerging pharmacological therapies suppress the central 
hyper­excitability associated with the pathophysiology. 
A diversity of pharmacological targets and mechanisms 
such as bioamine modulation, subunits, NMDA receptors, 
melatonin receptors and cannabinoid receptors, has been identi ed at which drugs act to demonstrate effectiveness in the management of the symptoms of FM. Although eficacy 
has been demonstrated by many of the drug treatments 
discussed leading to improved health status in patients with 
FM, outcomes related to individual mechanisms of action 
were not always consistent and not all symptoms were controlled by a single drug. The modest and limited eficacy 
often observed may reflect the heterogeneity of FM with 
existence of subpopulations of patients, the contribution of 
peripheral and central components to the pathophysiology, 
and the extensive range of accompanying co­morbidities. 
Although the optimal treatment approach would be drug 
monotherapy, the complexity and multidimensional nature 
of FM emphasizes the need for a pharmacology targeting 
multiple molecular mechanisms. In addition to biological 
variables psychological and social factors have been identi ed to contribute to the complexity of FM supporting 
consideration of a biopsychosocial model. Nevertheless, 
clues to underlying mechanisms as novel and potential 
targets for new medications are being provided by advances 
in the understanding of the pathophysiology of FM. 
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